Your browser doesn't support javascript.
loading
Cardiovascular and renal diseases in type 2 diabetes patients: 5-year cumulative incidence of the first occurred manifestation and hospitalization cost: a cohort within the French SNDS nationwide claims database.
Blin, Patrick; Joubert, Michael; Jourdain, Patrick; Zaoui, Philippe; Guiard, Estelle; Sakr, Dunia; Dureau-Pournin, Caroline; Bernard, Marie-Agnès; Lassalle, Régis; Thomas-Delecourt, Florence; Bineau, Sébastien; Moore, Nicholas; Droz-Perroteau, Cécile.
Afiliação
  • Blin P; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France. Patrick.blin@u-bordeaux.fr.
  • Joubert M; Diabetes Care Unit, Caen University Hospital, UNICAEN, Caen, 14033, France.
  • Jourdain P; APHP Bicêtre University Hospital, Bicêtre, France.
  • Zaoui P; Grenoble University Hospital, Grenoble, France.
  • Guiard E; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
  • Sakr D; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
  • Dureau-Pournin C; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
  • Bernard MA; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
  • Lassalle R; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
  • Thomas-Delecourt F; Astra-Zeneca, Courbevoie, France.
  • Bineau S; Astra-Zeneca, Courbevoie, France.
  • Moore N; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
  • Droz-Perroteau C; Univ. Bordeaux, INSERM CIC-P 1401, Bordeaux PharmacoEpi, 146 rue Léo Saignat, Bordeaux, 33000, 33076, France.
Cardiovasc Diabetol ; 23(1): 22, 2024 01 09.
Article em En | MEDLINE | ID: mdl-38195491
ABSTRACT

BACKGROUND:

Myocardial infarction (MI), stroke, peripheral arterial disease (PAD), heart failure (HF) and chronic kidney disease (CKD) are common cardiovascular renal diseases (CVRD) manifestations for type 2 diabetes. The objective was to estimate the incidence of the first occurring CVRD manifestation and cumulative hospitalization costs of each CVRD manifestation for type 2 diabetes without CVRD history.

METHODS:

A cohort study of all type 2 diabetes free of CVRD as of January 1st 2014, was identified and followed-up for 5 years within the French SNDS nationwide claims database. The cumulative incidence of the first occurring CVRD manifestation was estimated using the cumulative incidence function, with death as a competing risk. Cumulative hospitalization costs of each CVRD manifestations were estimated from the perspective of all payers.

RESULTS:

From 2,079,089 type 2 diabetes without cancer or transplantation, 76.5% were free of CVRD at baseline with a mean age of 65 years, 52% of women and 7% with microvascular complications history. The cumulative incidence of a first CVRD manifestation was 15.3% after 5 years of follow-up with a constant linear increase over time for all CVRD manifestations The most frequent was CKD representing 40.6% of first occurred CVRD manifestation, followed by HF (23.0%), then PAD (13.5%), stroke (13.2%) and MI (9.7%). HF and CKD together reached about one patient out of ten after 5 years and represented 63.6% of first CVRD manifestations. The 5-year global cost of all CVRD hospitalizations was 3.9 billion euros (B€), i.e. 2,450€ per patient of the whole cohort, with an exponential increase over time for each specific CVRD manifestation. The costliest was CKD (2.0 B€), followed by HF (1.2 B€), then PAD (0.7 B€), stroke (0.6 B€) and MI (0.3 B€). CONCLUSIONS/

INTERPRETATION:

While MI, stroke and PAD remain classic major risks of complications for CVRD-free type 2 diabetes, HF and CKD nowadays represent individually a higher risk and cost than each of these classic manifestations, and jointly represents a risk and a cost twice as high as these three classic manifestations all together. This should encourage the development of specific HF and CKD preventive strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acidente Vascular Cerebral / Diabetes Mellitus Tipo 2 / Insuficiência Renal Crônica / Doença Arterial Periférica / Cardiopatias / Insuficiência Cardíaca / Hipertensão Renal / Infarto do Miocárdio Tipo de estudo: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Acidente Vascular Cerebral / Diabetes Mellitus Tipo 2 / Insuficiência Renal Crônica / Doença Arterial Periférica / Cardiopatias / Insuficiência Cardíaca / Hipertensão Renal / Infarto do Miocárdio Tipo de estudo: Diagnostic_studies / Etiology_studies / Health_economic_evaluation / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Aged / Female / Humans Idioma: En Ano de publicação: 2024 Tipo de documento: Article